Introduction
IL-24 is a tumor-suppressor/cytokine that is expressed in cells of the immune system, including monocytes and activated T cells, and in skin cells, including keratinocytes and melanocytes [1] [2] [3] [4] [5] . The tumor-suppressor function of IL-24 was first described by Fisher et al. [1] in terminally differentiated melanoma cells. Therefore, the cytokine was initially named 'melanoma differentiation-association gene 7 (MDA-7)' [1, 2] . IL-24 receptors are expressed primarily in the skin on keratinocytes [6, 7] , but also found on endothelial cells, lung, testis, ovarian cells, and some cancer cells including melanoma [8] . They were shown to consist of the class II heterodimeric receptors of IL-22R1/IL-20R2 and IL-20R1/IL-20R2 [9] . IL-24 protein, which is expressed in some primary melanoma tumors, is subsequently lost during melanoma tumor invasion and progression but remains detectable in a small number of advanced metastatic tumors [10] [11] [12] [13] . IL-24 causes growth suppression and apoptosis in tumor cells both in vitro and in vivo, including lung, pancreatic, and breast cancer cells, while demonstrating no apparent toxicity to normal cells [14] [15] [16] . Data from our laboratory further demonstrated the cytotoxicity of IL-24 to human melanoma cell lines. These data are consistent with the tumor suppressor functions attributed to IL-24. IL-24 is currently being studied in clinical trials for its potential therapeutic usefulness. In addition to its direct tumor suppressive effects, several studies confirm a bystander effect of the secreted protein from Ad.mda-7 gene therapy [8] such that IL-24 secreted from Ad.mda-7 transfected cells induced cell death in nontransfected tumor cells.
Preliminary data from our laboratory, which have been expanded in this report, revealed that coculture of A375, a human melanoma cell line, with high doses of IL-2 resulted in endogenous production of IL-24 in a dosedependent manner. However, another melanoma cell line, MeWo, did not show upregulation of IL-24 following IL-2 treatment. We have reported previously that stimulation of normal peripheral blood mononuclear cells with IL-2 resulted in upregulation of IL-24 protein probably because of stabilization of IL-24 mRNA [17] . These observations suggest a possible mechanism by which IL-2 acts directly on the melanoma cells causing upregulation of the tumor suppressor IL-24.
Recombinant human IL-2 treatment has been used to treat patients with metastatic melanoma since 1985, resulting in significant clinical benefits and long-term survival in a minority of patients with melanoma [18] [19] [20] . Objective responses have been observed in 15-20% of patients with melanoma, with 6-8% of patients achieving complete durable responses [21, 22] . IL-2 antitumor activity is thought to be mediated by activation of natural killer cells to lymphokine activated killing activity [23, 24] , in essence enhancing the patient's immune activity against melanoma. The toxic side effects associated with high dose IL-2 therapy severely limit its use to patients with healthier organ function and performance status, and thus it remains an obstacle to widespread treatment with IL-2. Presently it is impossible to predict responders before use of this expensive and toxic therapy. Therefore, it is beneficial to establish a reliable marker to identify patients with melanoma who are most likely to respond to IL-2 therapy, as well as propose an additional mechanism of growth control that may be operating in vivo.
We now propose that one mechanism by which systemic IL-2 is able to generate a durable response in patients with melanoma is through direct activation of IL-24mediated tumor growth suppression via the IL-2R on some melanoma cells. IL-2R chains are reported to be present on the surfaces of cutaneous melanoma cells [25] [26] [27] [28] [29] , and IL-2 Rb has been identified in a number of cancer cell lines including small cell lung cancer, squamous cell carcinoma of the head and neck [30, 31] , and melanoma. We show here, through in-vitro experiments, that IL-2 leads to upregulation of IL-24 in a subset of melanoma cells resulting in IL-24-induced growth suppression. We propose that melanoma tumor cell IL-24 expression may be a potential predictive marker for IL-2 therapy.
Materials and methods

Cell lines and cell culture
Two human metastatic melanoma cell lines, A375 and MeWo, were obtained from the American Type Culture Collection (Rockville, Maryland, USA). The WM1341, WM793, and WM35 human primary melanoma cell lines were developed by Dr Meenhard Herlyn (Wistar Institute, Philadelphia, Pennsylvania, USA) [32] and were obtained from Dr Robert Kerbel (University of Toronto, Toronto, Ontario, Canada) [33, 34] . All cell lines were validated in 2009 by short tandem repeats (STR) DNA fingerprinting using the AmpFcSTR Identifier kit according to manufacturer instructions (Applied Biosystems, Foster City, California, USA). The STR profiles were compared with known ATCC fingerprints (ATCC.org), to the Cell Line Integrated Molecular Authentication database version 0.1.200808 (http://bioinformatics.istge.it/ clima/) [35] and to the MD Anderson fingerprint database. The STR profiles matched known DNA fingerprints or were unique. Cell lines used were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, California, USA) supplemented with 100 U/ml of penicillin, 100 mg/ml of streptomycin, 2 mmol/l L-glutamine, and HEPES buffer with 5% fetal bovine serum (FBS) (Life Technologies Inc., Grand Island, New York, USA). Experiments were run in supplemented RPMI with 2% charcoal stripped FBS (CSFBS). Serum was charcoal stripped to remove endogenous hormones and steroids by incubating overnight at 41C with a mixture of charcoal, dextran, sucrose, magnesium chloride, and HEPES buffer from Sigma-Aldrich (St Louis, Missouri, USA) following the manufacturer's protocol.
Reagents
Human recombinant IL-2 was obtained from Chiron (Emeryville, California, USA). The goal of this project was to mimic the conditions present in high-dose IL-2 patients during therapy. Patients receive 720 000 IU/kg/ dose every 8 h intravenously over 15-20 min with a maximum of 28 doses per course [36] . A study examining different cytokine levels in patients' serum showed that peak IL-2 levels averaged around 4000 U/ml and remained well above 1000 U/ml after the fourth dose [37] . On the basis of these data, we chose 1000 U/ml as a reasonable conservative dose at which to test the effects of high dose IL-2 on melanoma cells. IL-2 was therefore used at 1000 U/ml in all experiments. IL-15 was purchased from eBioscience (San Diego, California, USA). 7G11, a mouse anti-human IL-24 monoclonal antibody (Introgen Therapeutics, Houston, Texas, USA), was used for western blotting and for blocking IL-24 during growth assays. Mouse anti-human IL-2 monoclonal antibodies were purchased from BD BioSciences (San Jose, California, USA). Anti-IL-2 receptor (IL-2Ra, IL-2Rb, and IL-2Rg) antibodies were purchased from R&D Systems Inc., (Minneapolis, Minnesota, USA). Preimmune normal mouse IgG (Sigma-Aldrich) was used as a negative control for receptor blocking studies. Antiactin antibody from Santa Cruz Biotechnology (Santa Cruz, California, USA) was used as a standard loading control for all western blot staining. lipopolysaccharide (LPS) was purchased from Sigma-Aldrich.
Western blotting analysis
Cells were treated with brefeldin A (Sigma-Aldrich) at 10 mg/ml 4 h before harvesting, washed with cold PBS, and subsequently harvested into PBS. Western blot band protein quantification was performed using densitometry analysis with Scion Image software (Scion Corporation, Fredrick, Maryland, USA). Differences in protein levels between treatment conditions were determined by normalizing test proteins to b-actin controls within each sample.
Phospho-protein analysis by flow cytometry
Following the procedure described by Schulz et al. [38] cells were analyzed for expression of phosphorylated signal transducers and activators of transcriptions (STATs). Briefly cells were treated with 1000 U/ml IL-2 for 12-18 h before fixation with 1.6% paraformaldehyde followed by permeabilization at 41C with methanol. Cells were stained with PE mouse anti-STAT5 (pY694), PE mouse anti-STAT3 (pY705), or PE anti-STAT1 (pY701). These antibodies were purchased from BD Biosciences. Immunofluorescence was analyzed on a FACSCalibur with Cell Quest software (BD Biosciences).
Detection of secreted IL-24 protein
Cells were plated at 1 Â 10 6 cells/ml and cultured in supplemented RPMI-1640 medium (Invitrogen)+2% CSFBS with 1000 U/ml IL-2. Supernatants were harvested at 24 h and secreted IL-24 levels were determined by ELISA (R&D Systems Inc.).
Reverse transcriptase-PCR
RNA extraction was accomplished using the Qiagen RNAeasy (Valencia, California, USA) following the manufacturers protocol using the primers described in Table 1 . Reverse transcriptase (RT)-PCR assays were performed in the Quantitative Genomics Core Laboratory (QGCL) at The University of Texas Health Sciences Center in Houston, Texas. All PCR assays were designed and validated by QGCL staff to ensure they pass the minimum requirements for efficiency, sensitivity, and selectivity.
Growth suppression assays
Cells were plated at 5 Â 10 5 cells/well in 24 well plates, serum starved overnight, and then treated with RPMI+2% CSFBS with or without IL-2 at 1000 U/ml and other indicated conditions at day 0. Each condition was performed in triplicate. Cells were then harvested and viable cells counted using trypan blue dye exclusion at days 2-6 to assess cell growth. Mean values were determined for each condition and used for analysis.
Small interfering RNA assay siGENOME SMARTpool for human IL-24 and siGEN-OME NonTargeting small interfering RNA (siRNA) Pool were purchased from Dharmacon Inc. (Chicago, Illinois, USA). Oligofectamine was obtained from Invitrogen. Cells were serum starved overnight and then transfected with 2 nM IL-24 siRNA or control siRNA in OptiMEM media. Fresh RPMI+4% FBS was added 4 h after the transfection. Cells were transfected a second time 24 h after the initial transfection and harvested 24 h later. RNA was extracted and analyzed for IL-24 mRNA levels by RT-PCR. For growth suppression assays, supplemented RPMI+2% CSFBS media and IL-2 were added 24 h after the second transfection. This time point was designated day 0, and viable cells were counted at day 6 using the trypan blue dye exclusion assay.
Statistical analysis
Means and standard errors for each of the variables were determined and Student's t-test was utilized to evaluate the statistical significance of the experimental results. All experiments were performed at least three times unless otherwise indicated. Statistical significance was set at P < 0.05.
Results
Melanoma cell lines express IL-24 mRNA
Five melanoma cell lines representing various stages of disease and mutation status ( Fig. 1a ) were examined by RT-PCR for the presence of IL-24 message. A375, WM1341, and WM793 were shown to contain IL-24 message, whereas WM35 and MeWo had very low or undetectable levels of IL-24 mRNA ( Fig. 1b ).
IL-2 upregulates IL-24 protein production and secretion in IL-24-positive cell lines
Melanoma cells were treated with IL-2 at 1000 U/ml in RPMI+2% CSFBS for 24 h. Western blots are shown here for the three responsive cell lines ( Fig. 2a ). IL-24expressing cell lines, A375, WM793, and WM1341 showed statistically significant increases in levels of IL-24 protein when treated with high dose IL-2 compared with cells cultured in media alone ( Fig. 2a ). Treatment with LPS served as a positive control causing increased expression of IL-24 in all three cell lines. IL-24 protein was visualized as monomeric species with molecular weights ranging from 18 to 32 kDa [39] . IL-24 contains three distinct N-glycosylation sites, which account for the immunoreactivity of multiple bands that our IL-24 antibody detects during western blot analysis.
A375 exhibited an average increase in IL-24 levels of 43.0% (P = 0.01) when treated with IL-2, whereas WM1341 showed an increase of 31.6% (P < 0.01) and WM793 had an increase of 27.4% (P < 0.01). In contrast, WM35 and MeWo cells did not produce detectable levels of IL-24 regardless of treatment with IL-2 or LPS (data not shown); this is consistent with our mRNA data showing little or no IL-24 message in these two cell lines.
In support of these observations, enzyme-linked immunosorbent assay analysis showed that IL-2 treatment also caused an increase in IL-24 secretion in A375 by 36% (P = 0.02), in WM1341 by 44% (P < 0.01), and in WM793 by 28% (P = 0.01) ( Fig. 2b ). WM35 and MeWo cells did not secrete any detectable levels of IL-24.
To determine whether the increases in IL-24 levels were specifically because of the actions of IL-2, we neutralized IL-2 by preincubating with a mouse-anti-IL-2 antibody for 1 h at room temperature before stimulating the cells. Neutralization of IL-2 resulted in an inhibition of its effects on IL-24 bringing levels down to below baseline. A representative western blot from the IL-24-positive cell line WM1341 is shown in Fig. 2c . These results indicate that the elevations of IL-24 in these cells are a direct result of treatment with IL-2.
Blocking IL-2 R in melanoma cells suppresses IL-2 effects
As IL-2 has a direct effect on some melanoma cells, we examined IL-2 receptor expression on these cells. IL-2 mediates its effects on T cells by binding and signaling through the IL-2 receptor [40] . The receptor complex is composed of three chains -a, b, and g -which in different combinations form intermediate-affinity and high-affinity receptors for IL-2 [41, 42] . Each of the five cell lines was found to have measurable IL-2Rb and IL-2Rg mRNA when analyzed by RT-PCR (Fig. 3a) . IL-2Ra message was below the limit of detection of our assay in all the cells analyzed.
We demonstrated that these receptors on melanoma cells were functional by stimulating with IL-2 and examining cells for downstream signaling events. Ligand binding to IL-2Rb and IL-2Rg leads to activation of STAT3 and STAT5 and in some cells STAT1 [43, 44] . Activation of STAT1, 3, or 5 was determined by phospho-STAT analysis by flow cytometry. Shown in Fig. 3b are the results of stimulating A375 with IL-2 and intracellular staining for phospho-STAT1, 3 and 5. Activation of STAT1 and STAT5 was demonstrated by an increase in anti-phospho-STAT1 and phospho-STAT5 binding to the IL-2 stimulated populations (solid line histogram), compared with cells treated in media alone (dotted line histogram). IL-2 did not cause activation of STAT3 in A375. The control condition for these experiments was A375 stimulated with IFNg,which resulted in activation of STAT1 and to a less extent STAT3 and STAT5.
To confirm that IL-2 signals specifically through its receptor to upregulate IL-24 in these cells, the IL-2R was blocked by preincubating WM1341 (Fig. 3c ) and A375 cells (data not shown) with antibodies specific for each of the three IL-2 receptor chains. Blocking the IL-2R chains before adding IL-2 resulted in a decrease of 10-50% in IL-24 levels as compared with unblocked cells. This inhibition was most dramatic when IL-2Rb was blocked, suggesting that the IL-2Rb chain is essential for IL-2 upregulation of IL-24 expression.
IL-15 upregulates IL-24 expression in melanoma cell lines
Having demonstrated the importance of IL-2Rb on these melanoma cells, we examined whether IL-15, which shares both the IL-2Rb chain and IL-2Rg chain with IL-2 [45, 46] , would affect the expression of IL-24 in melanoma cells. Cells were stimulated with IL-15 (500 U/ml) for 24 h and cell lysates were analyzed by western blot analysis for IL-24 protein. All three IL-24-positive cell lines showed upregulation of IL-24 when treated with IL-15 ( Fig. 4) . Significantly, in A375 and WM1341, this increase was higher than that seen with high dose IL-2 stimulation. These data, together with the IL-2 receptor blocking experiment, confirm the significance of IL-2Rb for IL-24 upregulation.
IL-2 and IL-15 cause growth suppression in IL-24-expressing melanoma cells
RT-PCR showed that IL-2Rb and IL-2Rg message are present in melanoma cell lines (Fig. 3a) . It has been reported that several other cancers including squamous cell carcinoma, renal cell carcinoma, and gastric carcinomas are growth inhibited by IL-2 signaling specifically through the IL-2Rb chain [31, 47] . We hypothesized that the growth of melanoma cell lines expressing IL-2R may be affected by IL-2. Therefore, cells were grown with or without IL-2 added at day 0 and cell viability assessed on days 2-6. WM1341 and WM793 cells treated with IL-2 had significantly fewer viable cells by day 4 (P r 0.01), whereas A375 showed statistically significant growth suppression with IL-2 by day 5 (P = 0.04) ( Fig. 5a ). By day 6, IL-2-treated cells exhibited 18-32% less growth than untreated cells. The growth of the IL-24negative cell lines WM35 and MeWo was unaffected by treatment with IL-2 ( Fig. 5b) . Although WM35 cells had the highest level of IL-2Rb ( Fig. 3a) , IL-2 had no effect on its growth, suggesting that IL-2-mediated growth suppression is dependent on the IL-24 expression status of the cells. We also tested the effect of IL-15 treatment on growth suppression in A375 cells (Fig. 5c ). Results showed that cells treated with IL-15 demonstrated significant growth suppression of approximately 19-25% over days 4-6 (P = 0.02 by day 4). These results are comparable to those cells treated with IL-2.
IL-2-mediated growth suppression is dependent on IL-24
On the basis of our data which showed that treatment with IL-2 caused increased IL-24 protein production and secretion in some melanoma cell lines, we predicted that these amplified levels of IL-24 would subsequently cause growth suppression in those cell lines. Therefore, we attempted to block the effects of the secreted IL-24 with an anti-IL-24 monoclonal antibody and by silencing IL-24 mRNA with IL-24 siRNA.
Melanoma cell lines were treated with anti-IL-24 monoclonal antibody to block the effects of secreted IL-24. In these cells, anti-IL-24 antibody effectively reversed the growth suppression induced by IL-2 treatment (Fig. 6) . These data indicate that IL-2mediated growth suppression in melanoma cell lines is due to IL-24.
To directly block IL-24 production A375, WM1341, and WM35 were treated with IL-24 siRNA or a noncoding siRNA negative control for 48 h before the addition of high dose IL-2 on day 0. IL-24 knock-down was verified by RT-PCR for IL-24 message in cells transfected with either noncoding control siRNA or IL-24 siRNA (Fig. 7b ). Cell viability was assessed at day 6 ( Fig. 7a) . Results of growth suppression assays showed that in the two IL-24-positive cell lines, A375 and WM1341, silencing IL-24 at the mRNA level neutralized the IL-2-mediated 
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Functional IL-2Rb and IL-2Rg are expressed in melanoma cell lines and blocking IL-2R suppresses IL-2 effects. IL-2Rb and IL-2Rg are expressed on melanoma cells as determined by reverse transcriptase-PCR (a). These receptors are functional as shown by activation of STAT1 and 5 after stimulation with IL-2. Shown (b) are phospho-STAT1 (left histograms, upper row) and phospho-STAT5 (right histogram, upper row) expression in A375 stimulated overnight with media (dotted line) or IL-2 (solid line) and measured by phospho flow cytometry. STAT3 is not activated by IL-2 treatment (center histograms, upper row, solid line). Positive controls for these experiments are A375 treated with IFNg (solid line histogram) where phospho-STAT1 (left histograms, lower row) as well as phospho-STAT3 (center histogram, lower row) and phospho-STAT5 (right histogram, lower row) cells are detected. Pretreatment of WM1341 with anti-IL-2Rb or anti-IL-2Rg inhibited the expression of IL-24 in cells treated with IL-2 as measured by immunoblotting (c). The graph shows relative IL-24 expression levels determined by densitometry and normalized against b-actin.
growth suppressive effects previously observed; in these cell lines, there was no significant difference seen between the IL-24 silenced cells that were cultured with IL-2 and those without IL-2. In A375 and WM1341, IL-2 maintained its growth suppressive effects within all of the control groups (P r 0.05). In WM35, an IL-24negative cell line, treating with IL-24 siRNA had no effect on growth between IL-2-treated and nontreated cells. These data further confirm that IL-2-mediated growth suppression is directly dependent on IL-24.
Discussion
We have established a novel mechanism of IL-2 action in melanoma by demonstrating that high dose IL-2 had a direct effect on a subset of melanoma cells. These cells expressed functional IL-2 receptors and upregulated their expression of IL-24 mRNA, protein expression and secretion, leading to growth suppression. Furthermore, we showed that IL-2 mediates this activity by signaling through the IL-2 receptor, in particular the IL-2Rb chain in these cells. Finally, we demonstrated that IL-15, which shares the IL-2Rb chain with IL-2, also upregulated IL-24 protein expression and resulted in growth suppression in IL-24-positive cells.
IL-2 mediates its actions by binding to its receptor resulting in activation of Ras/MAPK, JAK/Stat, and PI3kinase/Akt signaling pathways leading to downstream gene transcriptional regulation [43, 44, 48] . As an immunotherapeutic agent, IL-2 directs its antitumor functions through cell-mediated immunity. Although reports exist of IL-2R and direct IL-2 effects on cancer cells, the mechanism of action is still unclear. One group has reported that IL-2 at low doses in the absence of serum appeared to stimulate proliferation of some melanoma cell lines but not others during the first 24 h, whereas cell growth was unaffected, or somewhat suppressed, at higher doses around 500 U/ml over the same time period [25] .
IL-2 has been shown to directly inhibit the growth of human squamous cell carcinoma of the head and neck (SCCHN) both in vitro and in nude mice bearing SCCHN xenografts [31, 47, 49, 50] . Growth inhibition in SCCHN cells was completely reversed by blocking with an anti-IL-2Rb antibody and partially reversed by blocking with an anti-IL-2Ra antibody; this indicated the importance of the intermediate affinity IL-2R for the growth suppressive effect of IL-2 in cancer cells. These reports support our data that IL-2 signals through the IL-2Rb chain and has a direct growth suppressive effect on melanoma cells.
Although a valuable and established cancer immunotherapy, IL-2 is successful in a subset of patients and can result in severe toxic side effects. The availability of positive predictive biomarkers of IL-2 response would significantly improve targeted therapy for melanoma. Accordingly, our study suggests that IL-24 may be such a marker. It is possible that the patients with durable responses to high dose IL-2 therapy have melanoma cells that increase their expression of IL-24 in response to IL-2. Therefore, establishing the IL-24 status of melanoma tumors could help identify patients who would benefit most from IL-2 treatment despite its negative side effects.
We have shown that upregulation of IL-24 through the actions of IL-2 results in IL-24-mediated melanoma growth suppression. In addition, the increased secretion of IL-24 could also have a paracrine effect by impacting neighboring cells within the tumor microenvironment. This is highly possible as it has been reported that the IL-24 receptor chains are present on melanoma cell lines [8] . Even if only a fraction of melanoma cells within a tumor are capable of responding to IL-2, the remaining unresponsive cells, which may possess the IL-24 receptor, could be indirectly affected by the secreted IL-24 from responding cells resulting in their growth arrest. Of the individual cell lines used in this paper, FACs analysis confirms that 6-12% of cells within each cell line expressed IL20R1 and 17-23% expressed IL22R1 (data not shown).
On the basis of the data contained in this manuscript and the available literature reviewed, we have presented a novel model for the direct effects of IL-2 on melanoma cells. We propose that treatment with IL-2 can upregulate IL-24 protein expression in some tumor cells leading to melanoma tumor growth suppression. Currently, no reliable marker exists to identify and predict the patients with melanoma who are most likely to respond positively to IL-2 therapy. The results from this study offer insights into several potential predictive biomarkers for targeted IL-2 therapy. Potential markers include the presence of IL-24 or coexpression of IL-24 and the IL-2Rb chain in melanoma cells. Other potential markers previously presented in the literature include vascular endothelial growth factor (VEGF) as high serum levels of VEGF were correlated with lack of clinic response to IL-2 [51] .
IL-24 has been shown to inhibit VEGF production at a translational level in human prostate cancer cells, consistent with our model [52] .
This study also offers evidence to support the exploration of IL-15 either alone or in combination with other treatments as a potential therapy for melanoma. We have shown IL-15 to be equally capable of causing IL-24-dependent melanoma cell growth suppression in comparison with IL-2, and the existing literature observes that IL-15 has fewer side effects and toxicity than high dose IL-2 therapy. It has been published that NSAIDs can also induce IL-24 protein expression and subsequent apoptosis and growth arrest both in vitro and in vivo [53] . It is possible that IL-2 or IL-15 could be used in conjunction with therapies such as NSAIDs, which might synergistically intensify the IL-24-dependent growth suppressive effects in cancer cells.
Cancers are incredibly complex diseases, and increasing our understanding of the molecular mechanisms of both the diseases and the treatments is essential. Selection of an appropriate therapy should be tailored to the individual patient based on his specific tumor and immunologic profile. It is our hope that this work suggests IL-24 as IL-2 melanoma cell growth suppression is dependent on IL-24. Melanoma cells, those that express IL-24 protein, were grown with IL-2 at 1000 U/ml (') or media alone (~) for 6 days. Cells were preincubated with anti-IL-24 monoclonal antibody and grown with IL-2 (&); or preincubated with mouse IgG and grown with IL-2 (*) for 6 days. Cell growth was measured daily for 6 days by trypan blue exclusion. Results are reported as total cell number per culture. All experiments were set up in triplicate cultures and repeated twice. Shown are representative results for each cell line. *P < 0.05 comparing the total cell number of cells grown in media alone compared with those grown with IL-2.
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a potential predictive marker for IL-2 responsiveness, and provides the basis of an identifiable targeted therapy for melanoma in a subset of patients. Our laboratory is currently testing tumors from patients treated with high dose IL-2 for expression of IL-2R as well as IL-24 mRNA and protein. 
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Silencing IL-24 reverses IL-2-induced growth suppression. IL-24 small interfering RNA (siRNA) inhibits IL-2-induced growth suppression in melanoma cells (a). Growth was assessed at day 6 in siRNA-transfected melanoma cells treated with IL-2 at day 0. Data are presented as % growth inhibition, which is equal to [1 -(total cell number of cells grown with IL-2/total cell number of cells grown in media alone)] Â 100%. IL-24 siRNA specifically knocked down the expression of IL-24 in these cells compared with cells treated with noncoding siRNA as shown by reverse transcriptase-PCR analysis (b). Results are expressed relative to b-actin.
